SuperworthIQVIA Holdings Inc. IQV
Medical - Diagnostics & Research, Healthcare
$256.38
−0.67%
- Market cap
- $42.2B
- PE
- 32.0×
- 10y median 35.0×
- Forward PE
- Price to sales
- 2.5×
- EV/EBIT
- 25.7×
- Revenue, 12 months
- $17B
- +8% on a year ago
- Net margin
- 8.1%
- Free cash flow yield
- 5.1%
IQVIA trades at 32.0× trailing earnings, near its ten-year median. Revenue was $17B over the last twelve months, up 8% on a year earlier with a 8% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.9B | $3.7B | $3.8B | $3.9B | $4B+2% | $3.8B+3% | $4B+5% | $4.1B+5% | $4.4B+10% | $4.2B+8% | $4.4B+9% | |
| Cost of revenue | $2.5B | $2.4B | $2.8B | $2.5B | $2.6B+4% | $2.5B+4% | $2.7B−2% | $2.7B+8% | $2.9B+14% | $2.8B+11% | $2.9B+9% |
| Gross profit | $1.4B | $1.3B | $1.1B | $1.4B | $1.4B−1% | $1.3B+0% | $1.3B+25% | $1.4B−0% | $1.4B+4% | $1.4B+4% | $1.4B+9% |
| SG&A | $556M | $508M | $509M | $522M | $453M−19% | $508M+0% | $509M+0% | $514M−2% | $468M+3% | $502M−1% | $574M+13% |
| $501M | $506M | $520M | $550M | $626M+25% | $496M−2% | $506M−3% | $553M+1% | $627M+0% | $514M+4% | $506M+0% | |
| Interest expense | $181M | $166M | $163M | $170M | $171M−6% | $165M−1% | $182M+12% | $189M+11% | $193M+13% | $192M+16% | $197M+8% |
| Pre-tax income | $373M | $340M | $436M | $349M | $544M+46% | $323M−5% | $323M−26% | $408M+17% | $537M−1% | $328M+2% | $301M−7% |
| −$102M | $49M | $75M | $65M | $112M | $61M+25% | $56M−25% | $76M+17% | $59M−47% | $59M−3% | $60M+7% | |
| Net income | $469M | $288M | $363M | $285M | $437M−7% | $249M−14% | $266M−27% | $331M+16% | $514M+18% | $274M+10% | $256M−4% |
| $2.54 | $1.56 | $1.97 | $1.55 | $2.42−5% | $1.40−10% | $1.54−22% | $1.93+25% | $2.99+24% | $1.61+15% | $1.53−1% | |
| 184.3M | 184.3M | 184.3M | 184.2M | 180.8M−2% | 177.4M−4% | 173.2M−6% | 171.7M−7% | 171.9M−5% | 169.8M−4% | 167.3M−3% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Medical - Diagnostics & Research within ten times IQVIA's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| IQVIQVIA Holdings Inc. | $42.2B | 32.0× | 35.0× | 2.5× | +8% | 8.1% | |
| WATWaters Corporation | $42B | 109× | 29.3× | 9.2× | +52% | 3.6% | |
| IDXXIDEXX Laboratories, Inc. | $40.4B | 35.6× | 54.8× | 8.8× | +13% | 25.0% | |
| ILMNIllumina, Inc. | $39.5B | 49.9× | 50.6× | 9.0× | +5% | 18.4% | |
| AAgilent Technologies, Inc. | $47.2B | 33.3× | 32.4× | 6.5× | +9% | 19.5% | |
| MTDMettler-Toledo International Inc. | $30.6B | 34.5× | 36.5× | 7.4× | +7% | 21.9% | |
| LHLabcorp Holdings Inc. | $25.5B | 25.8× | 21.9× | 1.8× | +6% | 7.0% | |
| DGXQuest Diagnostics Incorporated | $25.3B | 24.1× | 19.1× | 2.2× | +10% | 9.2% | |
| DHRDanaher Corporation | $151.8B | 38.8× | 36.4× | 6.1× | +5% | 15.9% | |
| TMOThermo Fisher Scientific Inc. | $239.9B | 35.6× | 32.8× | 5.3× | +7% | 15.0% | |
| Peer median | $40.4B | 35.6× | 32.8× | 6.5× | +7% | 15.9% |
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .